Heptares and Takeda to collaborate on CNS drug discovery

Venture-capital backed Heptares Therapeutics Ltd of the UK has received £1.7 million upfront in a collaboration deal with the Takeda Pharmaceutical Company to discover drugs for central nervous system disorders focused on a GPCR target.